Catalent Inc (NYSE:CTLT)

109.94
Delayed Data
As of Aug 12
 0.00 / 0.00%
Today’s Change
86.34
Today|||52-Week Range
142.64
-14.13%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$19.7B

Company Description

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment consists of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment involves packaging, storage, distribution, and inventory management for

Contact Information

Catalent, Inc.
14 Schoolhouse Road
Somerset New Jersey 08873
P:(732) 537-6200
Investor Relations:
(732) 537-6325

Employees

Shareholders

Mutual fund holders62.31%
Other institutional27.48%
Individual stakeholders17.65%

Top Executives

Alessandro MaselliPresident, Chief Executive Officer & Director
Thomas P. CastellanoSenior VP, Chief Financial & Accounting Officer
Greg BleckVice President-Biologics Research & Development
Kay SchmidtSenior Vice President-Technical Operations
Lim Chin WeiManager-Global Scientific Affairs